Ethical challenges in outbreak trial design: from Ebola to Nipah.

Authors

Euzebiusz Jamrozik, Lucie Abeler-Dörner, Amol Chaudhari, Phaik Yeong Cheah, Robert Hinch, Richard Jarman, Tess Johnson, Michael Parker, Carolin Vegvari, Nina Wressnigg, Christophe Fraser

Published in

Vaccine. Volume 89. Pages 128858. Jul 18, 2026. Epub Jul 18, 2026.

Abstract

Nipah virus causes sporadic outbreaks characterized by high mortality, with transmission concentrated within households and healthcare settings. Clinical trials of vaccines for high-mortality pathogens during outbreaks face significant methodological and ethical challenges, including due to short epidemic durations and variable community acceptance of standard individual randomized controlled trials (iRCTs). This paper examines key ethical issues in Nipah vaccine outbreak trial design. First, outbreak trials must recruit individuals at high risk of infection to reach efficacy endpoints before epidemics end, yet placebo controls may be controversial due to risks of infection among participants. Failure to accrue sufficient infections during outbreaks risks prolonged delays to vaccine licensure. Second, alternatives to classical iRCTs involve ethical and methodological trade-offs: cluster randomization may delay efficacy endpoints, especially when high transmission occurs in only a minority of clusters; trials involving delayed vaccination may involve similar risks (for control participants who are infected during the delay to vaccination) as for those in standard placebo iRCTs; and single arm trials risk failure to clarify vaccine efficacy due to their lack of controls. Third, although high pre-trial probability of experimental vaccine efficacy (>50% for recent Phase III vaccines) challenges traditional concepts of clinical equipoise, rigorous vaccine trials remain ethically acceptable. Fourth, policies for post-trial access to efficacious vaccines should be revised to provide accelerated access to control arm participants. Finally, ethical trial design depends on appropriate community engagement, which should begin early in outbreaks and ideally continue in inter-epidemic periods.

PMID:
42470890
Bibliographic data and abstract were imported from PubMed on 19 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.